HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) saw unusually-high trading volume on Friday . Approximately 96,135 shares traded hands during trading, a decline of 23% from the previous session's volume of 124,271 shares.The stock last traded at $20.44 and had previously closed at $19.42.
Analyst Upgrades and Downgrades
Several research firms have recently commented on HCM. The Goldman Sachs Group raised their price objective on shares of HUTCHMED from $17.00 to $19.00 and gave the company a "neutral" rating in a research note on Thursday, August 1st. StockNews.com cut shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Thursday, July 18th.
View Our Latest Report on HCM
HUTCHMED Stock Performance
The firm's 50-day moving average is $18.35 and its 200 day moving average is $18.41. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Institutional Trading of HUTCHMED
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bellevue Group AG lifted its stake in HUTCHMED by 2.1% during the first quarter. Bellevue Group AG now owns 1,154,632 shares of the company's stock worth $19,398,000 after purchasing an additional 23,521 shares during the last quarter. M&G Plc bought a new position in HUTCHMED during the first quarter valued at about $4,458,000. Renaissance Technologies LLC boosted its position in shares of HUTCHMED by 74.8% in the 2nd quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock valued at $2,248,000 after purchasing an additional 56,200 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in shares of HUTCHMED by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company's stock valued at $1,060,000 after purchasing an additional 4,877 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of HUTCHMED by 54.9% in the 1st quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company's stock valued at $721,000 after purchasing an additional 15,221 shares during the period. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
